METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients
METTL4 and METTL5 expression levels are strong predictors of HCC recurrence. The risk model offers a novel approach for postoperative management of HCC.
Authors
- Xiangnan Liang
- Danjing Guo
- Jialing Zhao
- Sunbin Ling (ORCID: https://orcid.org/0000-0003-0846-5489)
- Changku Jia (ORCID: https://orcid.org/0000-0002-6613-295X)
- Jianhui Li
- Liang Zhi
- Ruiqi Sun (ORCID: https://orcid.org/0000-0002-5433-2380)
Institutions
- Dalian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Blood Center of Zhejiang Province (CN)
- Zhejiang Shuren University (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/14796694.2024.2442296
- Citations
- 4
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Natural Science Foundation of Zhejiang Province